Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

We recently published a list of 10 Best Bank Stocks to Buy in 2025. In this article, we are going to take a look at where ...

If you're looking to open a high-yield savings account, American Express and Marcus by Goldman Sachs both offer excellent ...

Goldman Sachs Group Inc.'s stock was up 1.3% to $614 a share on Thursday, a record stock price for the investment bank, a day after its stronger-than-expected fourth-quarter profit. If the gains hold ...

Goldman Sachs Group, Inc. (GS) is currently at $612.34, up $6.42 or 1.06% --Would be new all-time high (Based on available data back to May 4, 1999) --Would be the first record close since Nov. 29, ...

Goldman estimates that companies could spend some $1.07 trillion on buying back their own stock this year. On the other side ...

Morgan Stanley's profit increased in the fourth quarter, fueled by a wave of dealmaking and stock sales that drove its ...

Analyst Betsy Graseck from Morgan Stanley maintained a Buy rating on Goldman Sachs Group (GS – Research Report) and increased the price target ...

The Australian dollar’s recent decline has turned the country into a “treasure island” for offshore dealmakers, according to ...

Asian markets extended a global rally Thursday after below-forecast US inflation provided a much-needed shot of relief to ...

At an event hosted by Cisco on Wednesday, Goldman Sachs CEO David Solomon indicated that the multi-year IPO drought should be coming to an end.

Wall Street CEOs voiced confidence on Wednesday that the incoming administration would be business-friendly and good for banks.